Pharmaceutical Preparations · CIK 1600620
Aurinia Pharmaceuticals delivers therapies for autoimmune diseases, including the FDA-approved LUPKYNIS for lupus nephritis
Comparable business profile · signals at a glance
Coverage (30d): 1 reputable article.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
In the 90 days to Mar 3, 2026: 1 insider bought $12.7M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 3, 2026 | Tang KevinDirector | Buy | 184,208 | $14.22 | $2.6M |
| Mar 2, 2026 | Tang KevinDirector | Buy | 115,792 | $14.21 | $1.6M |
| Mar 2, 2026 | Tang KevinDirector | Buy | 83,561 | $14.33 | $1.2M |
| Feb 27, 2026 | Tang KevinDirector | Buy | 300,000 | $13.90 | $4.2M |
| Feb 27, 2026 | Tang KevinDirector | Buy | 214,839 | $14.12 | $3.0M |
| Feb 27, 2026 | Tang KevinDirector | Buy | 1,600 | $14.38 | $23K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.